Vilon is a synthetic dipeptide (Lys-Glu, abbreviated “KE”) from the Khavinson “bioregulator” family, marketed for immune and thymic support. It is one of the better-studied compounds in this family, with published animal work (including tumor-bearing and lifespan studies in mice) as well as human skin-cell laboratory work, though still no completed human clinical trial identified in this review. It is not an approved drug anywhere and is sold as an oral capsule or research peptide.
Research snapshot
| Peptide category | Khavinson-family short “bioregulator” dipeptide, marketed for immune/thymic support |
| Primary research interest | Immune-system and thymic aging support |
| Highest available evidence | Tier 3/4 — one of the better-studied compounds in this family, with published animal work (tumor-bearing and lifespan studies in mice) and human skin-cell laboratory work; no completed human clinical trial identified |
| Human research available | No completed human clinical trial identified; human skin-cell (in vitro) laboratory work exists |
| Development status | Not in formal pharmaceutical development; sold as an oral capsule/research peptide |
| Regulatory status | Not an approved drug anywhere |
| Last reviewed | September 2026 |
Technical identity
| Primary name | Vilon |
| Alternative names | KE (from its Lys-Glu sequence) |
| Peptide sequence | Lys-Glu (“KE”) |
| Amino-acid length | 2 (dipeptide) |
| Molecular formula | Not independently re-verified in this pass |
| Molecular weight | Not independently re-verified in this pass |
| CAS Registry Number | Not independently re-verified in this pass |
| PubChem CID | Not independently re-verified in this pass |
| Peptide class | Khavinson-group “bioregulator” peptide line (Saint Petersburg Institute of Bioregulation and Gerontology) |
| Primary biological target | Proposed immune/thymic gene-regulatory activity; not established via receptor-level human data |
| Developer or originator | Vladimir Khavinson’s research group, Saint Petersburg Institute of Bioregulation and Gerontology; developed as a synthetic analog intended to mimic thymic peptide extract activity |
| Development status | Not an approved or registered pharmaceutical anywhere identified in this review |
What it is
Vilon is a two-amino-acid peptide (lysine-glutamate, “KE”) developed by Vladimir Khavinson’s research group at the Saint Petersburg Institute of Bioregulation and Gerontology, originally studied as a synthetic analog intended to mimic the activity of thymic peptide extracts on immune-system aging. Unlike most of its sister compounds in this article series, Vilon has a somewhat more substantial published record, including an animal tumor/lifespan study and several human skin-fibroblast studies, making it one of the more frequently cited members of the Khavinson short-peptide family in the indexed literature.
It remains, however, a research compound rather than an approved medicine: the studies that exist come predominantly from the same research network (the Khavinson group and its close academic collaborators, largely published in Russian-language or Russian-affiliated journals), and no independent Western regulatory body has reviewed or confirmed its claimed mechanisms.
How does it work?
Plain-English explanation
The idea behind Vilon is that this very small peptide can help aging or stressed cells — particularly immune and skin cells — behave more like younger, healthier cells: dividing better, producing more of the structural proteins that keep skin firm, and showing fewer markers of cellular “wear and tear.” Animal studies have also looked at whether it can slow tumor growth and extend lifespan in mice.
Technical explanation
In an early study, the synthetic dipeptide vilon (L-Lys-L-Glu) was reported to inhibit the growth of spontaneous tumors and increase the life span of mice (Anisimov et al., cited via ResearchGate record of the original publication; the primary journal citation was not independently re-verified against PubMed in this review and should be treated as provisional pending direct confirmation). In human skin fibroblast aging cultures, KE increased collagen type I expression by roughly 83% in “old” fibroblast cultures and increased sirtuin-6 expression in both “young” and “old” cultures (Fridman, Linkova, Polyakova, et al., 2017, Adv Gerontol, PMID 29322736). In a separate skin-fibroblast-aging study, KE (alongside AED, KED, and AEDG) inhibited MMP-9 synthesis and enhanced markers of proliferation and cellular renewal (Ki-67, CD98hc) (Lin’kova et al., 2016, Bull Exp Biol Med, PMID 27259496, DOI 10.1007/s10517-016-3370-x). In bone-marrow mesenchymal stem cell aging models, KE was reported to modestly increase IGF1 expression and to increase FOXO1 expression in one aging model but not another (Ashapkin et al., 2020, Mol Biol Rep, PMID 32399807, DOI 10.1007/s11033-020-05506-3). No mechanistic data specific to thymic tissue or adaptive immune cell populations under controlled conditions were identified in this review, despite Vilon’s marketing as an “immune/thymic bioregulator.”
Potential benefits and research applications
Tumor growth and lifespan in animal models
What is being investigated: whether Vilon (KE) slows spontaneous tumor growth and extends lifespan. How the effect might occur: proposed immune-modulatory and anti-aging cellular effects. Evidence: a single, older published mouse study. Strength: preliminary/animal tier; the specific citation was not independently re-verified against a PubMed record during this review and should be confirmed before being presented as an established finding. Limitation: one study, in mice, has not been independently replicated in this review’s search, and does not establish any human anti-cancer effect.
Skin and connective-tissue cell aging
What is being investigated: whether KE increases collagen and other markers of youthful skin-cell function. How the effect might occur: proposed stimulation of collagen type I and sirtuin-6 expression. Evidence: published human skin fibroblast culture studies. Strength: preliminary, laboratory tier. Limitation: cell-culture increases in collagen expression do not establish a visible cosmetic effect in living skin.
Immune/thymic support (as marketed)
What is being investigated: vendor marketing positions Vilon as a thymic/immune bioregulator. How the effect might occur: historically modeled on thymic-extract peptide activity, per the Khavinson group’s stated rationale for developing it. Evidence: the mouse tumor/lifespan study is the closest available data point with plausible relevance to immune-surveillance function, but no dedicated thymic-tissue or immune-cell-population study was identified. Strength: has not been directly established for thymic bioregulation despite the marketing name; it is more directly supported for skin/fibroblast effects than for immune function specifically.
What dosage information circulates?
Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.
Amounts studied in human research
No completed, published human clinical trial with a specific KE dosing regimen was identified. Not consistently reported.
Amounts studied in animal research
The referenced mouse tumor/lifespan study reportedly used repeated low-dose administration of the dipeptide, but the specific amount, frequency, and route were not independently re-extracted from a verified primary source in this review; this should be confirmed against the original publication before being presented as a specific figure. Not consistently reported at the level of specificity this site requires.
Practitioner and community-reported protocols
Vendors selling Vilon as oral capsules or reconstituted 20 mg vials commonly describe roughly 10-20 mg per day for a 10-20 day course, matching the general Khavinson-line “bioregulator” template applied across this peptide family. This is widely repeated online, but its original source could not be verified as tracing to a dedicated clinical dosing study of Vilon.
Explanation of the reported figures
Vilon has somewhat more literature behind it than most peptides in this family, but the strongest single data point (the mouse tumor/lifespan study) could not be independently re-verified to a specific PubMed record with confirmed dosing details in this review, so its exact dose and schedule are not reported here as fact. The cell-culture work (skin fibroblasts, stem cells) used nanomolar concentrations applied directly to cultures, which cannot be converted into a human dose. The commonly repeated 10-20 mg, 10-20 day oral figure is a template shared across many unrelated Khavinson-family products and should not be read as Vilon-specific clinical guidance.
What circulates E5
Vendors and longevity/biohacking communities commonly describe oral Vilon capsule use at roughly 10-20 mg per day for a 10-20 day course, matching the generic Khavinson-line "bioregulator" course template used across this whole peptide family. This is widely repeated online, but its original source could not be verified, and it does not correspond to any confirmed human pharmacokinetic or dedicated clinical dosing study for Vilon specifically. Treat any specific "X mg/day" figure for Vilon as community/vendor-tier information only.
Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.
Side effects, risks, and limitations
No human trial exists to characterize side effects in people. As with other unregulated peptide products, purity, accurate labeling, contamination, and correct concentration are not guaranteed for vendor-sold Vilon. Long-term effects, interactions, and an appropriate human dose have not been established, and the immune-modulatory rationale behind the “thymic bioregulator” marketing has not been directly tested in dedicated immune-cell or thymic-tissue studies identified in this review.
Regulatory and developmental status
Vilon has no drug approval in the United States, European Union, or Russia identified in this review. It is sold as an oral “bioregulator” supplement and research peptide, not as a registered pharmaceutical, and has not entered a recognized clinical trial pipeline. Status verified as of the date below.
Frequently asked questions
What is Vilon?
A short synthetic dipeptide (Lys-Glu, “KE”) from the Khavinson bioregulator family, marketed as an immune/thymic support peptide and one of the more frequently studied compounds in this product line.
Has Vilon been studied in humans?
No completed human clinical trial was identified in this review; the available evidence is animal and human cell-culture research.
What dosage has actually been studied?
An older mouse study reportedly used repeated low-dose administration, but exact figures were not independently confirmed in this review. Cell-culture work used nanomolar concentrations, not a translatable human dose.
What dosage circulates online?
Vendors commonly describe roughly 10-20 mg oral courses over 10-20 days, but this figure is widely repeated without an identifiable original clinical source.
Does Vilon actually affect the thymus or immune system?
This is the compound’s marketing premise, but no dedicated thymic-tissue or immune-cell-population study was identified in this review; the closest supportive data point is an older mouse tumor/lifespan study.
Is Vilon approved anywhere?
No. It is not an approved medicine in any jurisdiction identified in this review.
What remains unknown?
Whether KE has any direct effect on thymic or immune tissue, what oral human dose (if any) is meaningful, and whether the mouse tumor/lifespan findings replicate or generalize.
Bottom line
Vilon (KE) is one of the more frequently studied Khavinson-family peptides, with published human skin-cell aging evidence and an older animal tumor/lifespan study, but it still has no completed human clinical trial and no dedicated evidence for its marketed thymic/immune claim. The oral capsule dosing that circulates commercially is a generic marketing template shared across this whole peptide family, not a studied clinical protocol. It remains an unapproved research/supplement peptide.